The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This chart collection compare health outcomes, quality of care, and access to services between the U.S. and peer countries. While inconsistent and imperfect metrics make it difficult to firmly assess system-wide health quality in the U.S., a review of the available data prior to the onset of the COVID-19 pandemic suggests that in most of these measures, the U.S. has lagged behind comparably large and wealthy countries.
This fact sheet provides an overview of the Ryan White Program, the largest HIV-specific federal grant program in the United States.
On July 16, 2022, the federally mandated crisis number, 988, became available to all landline and cell phone users at no charge. Since launch in July 2022, 988 has received 10.8 million calls, texts, and chats. In May 2024, monthly contacts exceeded half a million, up about one-third from a year ago and 80% since May 2022. Despite increased demand for 988 services, national answer rates improved and wait times decreased, though some gains slipped in the second year.
This updated fact sheet provides the latest data on the global HIV/AIDS epidemic, including impact on affected and vulnerable populations, treatment and prevention efforts, and an overview of the U.S. and global responses to the epidemic.
Substance use disorders contribute to a growing number of deaths, yet they often go undiagnosed and untreated. While nearly three-quarters of Medicaid enrollees with a diagnosed substance use disorder utilized some type of treatment service in 2020, medication treatment rates varied widely, being much lower for alcohol use disorder than opioid use disorder, and lower among Black enrollees and youth compared to their counterparts. Treatment rates varied considerably across states and average Medicaid spending for people with a diagnosed substance use disorder is over twice as high compared to those without a substance use disorder.
With the depletion of the federal-purchased supply of COVID-19 vaccines, treatments and tests following the end of the public health emergency, this resource provides an overview of the implications of these changes for access to people covered by Medicare, Medicaid and private insurance, as well as those who are uninsured.
This brief uses 2022 data from the National Substance Use and Mental Health Services Survey (N-SUMHSS), an annual survey sent to all substance use and mental health treatment facilities to assess the supply and characteristics of these facilities at a national and state level. Despite the escalation of mental health needs and the increasing and evolving opioid epidemic, accessing treatment continues to be difficult--as indicated by consumer surveys and national data. Factors like the decline in psychiatric beds, financing barriers, difficulty accessing outpatient treatment, and the growing workforce shortages have led to more reports of unmet need and psychiatric boarding in emergency departments. Overall, there are approximately 14,700 facilities providing substance use treatment services and about 9,500 facilities that offer mental health services. More than eight in ten substance use treatment facilities and mental health facilities provide outpatient services; smaller shares offers more intensive inpatient services. Substance use treatment and mental health bed availability varies across states. Most substance use and mental health treatment facilities are non-profit; however, for-profit ownership is more common among substance use treatment facilities, whereas public ownership is more common among mental health facilities. Most facilities report high participation with private insurance and Medicaid, but lower for Medicare and there is variation across states. Reported Medicaid participation by substance use treatment facilities varies across states.
This brief examines opioid use disorder diagnoses and medication treatment for opioid use disorders in the prenatal and postpartum period among people with a Medicaid-covered delivery in 2017-2018.
In addition to having the highest obesity rates, the U.S is currently facing significantly higher prices for several major drugs used for weight loss and other health needs, according to a new KFF analysis of the list prices for semaglutide and tirzepatide drugs.
A class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment.
© 2025 KFF